Daily use of a polypill composed of a statin, a beta-blocker, an angiotensin-converting enzyme inhibitor and hydrochlorothiazide reduced the incidence of cardiovascular disease (CVD) in TIPS-3 (International Polycap Study-3).
In the trial, investigators randomly assigned 5,713 patients in a 1:1 fashion to receive either a daily capsule composed of simvastatin (40 mg), atenolol (100 mg), ramipril (10 mg) and hydrochlorothiazide (2 mg) or placebo, then further randomized them in a